ARCHIVES

Gilotrif Increases PFS Compared to Erlotinib In LUX-Lung 8 Phase III Head-to-Head Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 10 | October 31, 2014

Download PDF Visit The Full Archive

Related Articles

Cancer Genome Atlas Researchers Link Cell Metabolism Pathways To Disease Aggressiveness

July 26, 2013

R. Lee Clark to Retire; Texas Starts Search for Successor

September 9, 1977

FDA Approves 35 Medicines In Fiscal 2012, Eight in Cancer

December 28, 2012

House Bill, Report Do Not Include Any Earmarks Or Directives To Aid CCOP, Centers, Cancer Control

August 7, 1987

NCI Program Announcements

May 5, 2000

Analyzing Tumor Tissue In Clinical Trials Can Improve Outcomes, RTOG Trial Finds

May 27, 2011